GlaxoSmithKline PLC
- GSK
- NYSE
- Consumer Products
- Latest 52.47
- Currency US$
- Change -0.27
- Percent Change -0.512 %
- Volume 1,352,247
- Tue Jun 18, 2013 4:02 PM EDT NYSE data delayed 15 minutes.
The Globe and Mail
- Open 52.37
- Previous Close 52.74
- High 52.57
- Low 52.194
- Bidx 52.29
- Askx 53.49
- 52-week High -- 54.00
- 52-week Low -- 41.68
- Beta 0.504
- Market Cap 128,655.39M
- EPS 2.69
- P/E 19.51
- Forward P/E 13.351
- PEG 2.30
- Annual Dividend 2.201
- Yield 4.195
News
- Renaissance and GlaxoSmithKline Agree to a Transfer of Nine Products
- Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist? (trametinib) tablets, approved by FDA as single-agent therapies
- From Novel Research to Innovative Medicines: GlaxoSmithKline Launches Discovery Fast Track Competition for Academic Researchers
- BREO? ELLIPTA? gains US approval for the treatment of COPD
- FDA Advisory Committee recommends approval of BREO? ELLIPTA? for the treatment of COPD
Financials & Calendars
- Sales $41,378,270,000
- Earnings $6,624,000,000
- Return on Equity 58.80%
- Cash Flow --
- Cash $5,481,450,000
- Current Ratio 1.18
12 months ended Mar 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
- Assets $66,641,300,000
- Liabilities $54,806,760,000
- Liabilities-to-Equity Ratio 4.63
Price Ratios
- Price to Sales 3.11
- Price to Book 10.87
- Price to Cash Flow n/a
Event Calendar
| Event | Last | Next | ||
|---|---|---|---|---|
| Earnings | Apr 24 | $0.77 | Jul 24 | $0.88 |
| Surprises | Apr 24 | 6.49% | n/a | n/a |
| Dividends | May 8 | $0.55 | n/a | n/a |
| Splits | n/a | -- | n/a | n/a |
12 months ended Jun 19, 2013.
A look at major corporate events and financial announcements that are coming up.
Company Information
About the Company
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Officers
- Sir Christopher Gent Chairman
- Andrew Witty Chief Executive Officer
- Company Type: n/a
- Company Status: n/a
- Full-time Employees: n/a
-
Incorporation:
United States,
n/a -
Top 1000 Ranking:
Profit: n/a
Revenue: n/a
Assets: n/a
Ideas & Discussion
Live Discussion of GSK on StockTwits